{"doi":"10.3389/fcimb.2021.809542","title":"A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae","abstract":"<jats:p>The increasing incidence of tigecycline resistance undoubtedly constitutes a serious threat to global public health. The combination therapies had become the indispensable strategy against this threat. Herein, 11 clinical tigecycline-resistant <jats:italic>Klebsiella pneumoniae</jats:italic> which mainly has mutations in <jats:italic>ramR</jats:italic>, <jats:italic>acrR</jats:italic>, or <jats:italic>macB</jats:italic> were collected for tigecycline adjuvant screening. Interestingly, ML-7 hydrochloride (ML-7) dramatically potentiated tigecycline activity. We further picked up five analogs of ML-7 and evaluated their synergistic activities with tigecycline by using checkerboard assay. The results revealed that ML-7 showed certain synergy with tigecycline, while other analogs exerted attenuated synergistic effects among tigecycline-resistant isolates. Thus, ML-7 was selected for further investigation. The results from growth curves showed that ML-7 combined with tigecycline could completely inhibit the growth of bacteria, and the time-kill analysis revealed that the combination exhibited synergistic bactericidal activities for tigecycline-resistant isolates during 24 h. The ethidium bromide (EtBr) efflux assay demonstrated that ML-7 could inhibit the functions of efflux pump. Besides, ML-7 disrupted the proton motive force (PMF) <jats:italic>via</jats:italic> increasing ΔpH, which in turn lead to the inhibition of the functions of efflux pump, reduction of intracellular ATP levels, as well as accumulation of ROS. All of which promoted the death of bacteria. And further transcriptomic analysis revealed that genes related to the mechanism of ML-7 mainly enriched in ABC transporters. Taken together, these results revealed the potential of ML-7 as a novel tigecycline adjuvant to circumvent tigecycline-resistant <jats:italic>Klebsiella pneumoniae</jats:italic>.</jats:p>","journal":"Frontiers in Cellular and Infection Microbiology","year":2022,"id":627928,"datarank":0.519860385419959,"base_score":3.4657359027997265,"endowment":3.4657359027997265,"self_citation_contribution":0.519860385419959,"citation_network_contribution":0.0,"self_endowment_contribution":0.519860385419959,"citer_contribution":0.0,"corpus_percentile":null,"corpus_rank":null,"citation_count":31,"citer_count":0,"citers_with_citation_signal":0,"citers_with_endowment":0,"datacite_reuse_total":2,"is_dataset":false,"is_dataset_confidence":null,"is_data_producer":false,"deposit_databanks":null,"is_oa":false,"file_count":0,"downloads":0,"has_version_chain":false,"published_date":null,"fair_score":null,"fair_percentile":null,"algorithm_id":"datarank_citation_only_1hop_v6","ranking_scope":"data_only","authors":[{"id":1625492,"name":"Lang Sun","orcid":null,"position":1,"is_corresponding":false},{"id":913388,"name":"Xue Li","orcid":"0000-0001-7073-7532","position":2,"is_corresponding":false},{"id":1625493,"name":"Xinxin Hu","orcid":null,"position":3,"is_corresponding":false},{"id":979570,"name":"Xiukun Wang","orcid":null,"position":4,"is_corresponding":false},{"id":1625494,"name":"Tongying Nie","orcid":null,"position":5,"is_corresponding":false},{"id":586765,"name":"Youwen Zhang","orcid":"0000-0002-0957-4276","position":6,"is_corresponding":false},{"id":1625495,"name":"Xuefu You","orcid":null,"position":7,"is_corresponding":false},{"id":1625491,"name":"Lilan Sun","orcid":null,"position":0,"is_corresponding":false}],"reference_count":0,"raw_metadata":{"has_enrichment":true,"resolved":true,"title":"A Novel Tigecycline Adjuvant ML-7 Reverses the Susceptibility of Tigecycline-Resistant Klebsiella pneumoniae","abstract":"<jats:p>The increasing incidence of tigecycline resistance undoubtedly constitutes a serious threat to global public health. The combination therapies had become the indispensable strategy against this threat. Herein, 11 clinical tigecycline-resistant <jats:italic>Klebsiella pneumoniae</jats:italic> which mainly has mutations in <jats:italic>ramR</jats:italic>, <jats:italic>acrR</jats:italic>, or <jats:italic>macB</jats:italic> were collected for tigecycline adjuvant screening. Interestingly, ML-7 hydrochloride (ML-7) dramatically potentiated tigecycline activity. We further picked up five analogs of ML-7 and evaluated their synergistic activities with tigecycline by using checkerboard assay. The results revealed that ML-7 showed certain synergy with tigecycline, while other analogs exerted attenuated synergistic effects among tigecycline-resistant isolates. Thus, ML-7 was selected for further investigation. The results from growth curves showed that ML-7 combined with tigecycline could completely inhibit the growth of bacteria, and the time-kill analysis revealed that the combination exhibited synergistic bactericidal activities for tigecycline-resistant isolates during 24 h. The ethidium bromide (EtBr) efflux assay demonstrated that ML-7 could inhibit the functions of efflux pump. Besides, ML-7 disrupted the proton motive force (PMF) <jats:italic>via</jats:italic> increasing ΔpH, which in turn lead to the inhibition of the functions of efflux pump, reduction of intracellular ATP levels, as well as accumulation of ROS. All of which promoted the death of bacteria. And further transcriptomic analysis revealed that genes related to the mechanism of ML-7 mainly enriched in ABC transporters. Taken together, these results revealed the potential of ML-7 as a novel tigecycline adjuvant to circumvent tigecycline-resistant <jats:italic>Klebsiella pneumoniae</jats:italic>.</jats:p>","is_dataset_classified":null,"base_score":0.0,"endowment":0.0,"datacite_reuse_total":2,"file_count":0,"downloads":0,"views":0,"has_version_chain":false,"is_dataset":false,"is_oa":false,"pmid":"35071055","pmcid":"PMC8766836","openalex_id":null,"authors":[],"funders":[{"funder_name":"Ministry of Science and Technology of the People&apos;s Republic of China","grant_id":"","title":null},{"funder_name":"Chinese Academy of Medical Sciences","grant_id":"","title":null},{"funder_name":"Peking Union Medical College","grant_id":"","title":null}],"total_grants":3,"fwci":null,"citation_percentile":null,"influential_citations":0,"citation_trend":[],"oa_status":"gold","license":"cc-by","oa_locations":[{"url":"https://doi.org/10.3389/fcimb.2021.809542","host_type":"publisher"},{"url":"https://www.frontiersin.org/articles/10.3389/fcimb.2021.809542/full","host_type":"publisher"},{"url":"https://doaj.org/article/a4a9634aae674817b3871725f7148611","host_type":"repository"},{"url":"https://www.ncbi.nlm.nih.gov/pmc/articles/8766836","host_type":"repository"},{"url":"https://europepmc.org/articles/PMC8766836","host_type":"Europe_PMC"},{"url":"https://europepmc.org/articles/PMC8766836?pdf=render","host_type":"Europe_PMC"}],"fields_of_study":[],"mesh_terms":["Humans","Klebsiella pneumoniae","Klebsiella Infections","Azepines","Minocycline","Naphthalenes","Anti-Bacterial Agents","Microbial Sensitivity Tests","Drug Resistance, Bacterial","Tigecycline"],"keywords":["Klebsiella pneumoniae","Resistance genes","Combination therapy","Tigecycline","Ml-7"],"sdg_mappings":[],"linked_datasets":[{"doi":"10.6084/m9.figshare.22624627.v1","title":"Additional file 1 of Clonal transmission of polymyxin B-resistant hypervirulent Klebsiella pneumoniae isolates coharboring blaNDM-1 and blaKPC-2 in a tertiary hospital in China","publisher":"figshare","resource_type":"JournalArticle"},{"doi":"10.6084/m9.figshare.22624627","title":"Additional file 1 of Clonal transmission of polymyxin B-resistant hypervirulent Klebsiella pneumoniae isolates coharboring blaNDM-1 and blaKPC-2 in a tertiary hospital in China","publisher":"figshare","resource_type":"JournalArticle"}],"clinical_trials":[],"software_tools":[],"database_accessions":[{"name":"gen"},{"name":"refseq"}],"source":"live","citation_network_status":"fetched"},"created_at":"2026-08-05T10:02:23.266686Z","pmid":null,"pmcid":null,"fwci":null,"citation_percentile":null,"influential_citations":0,"oa_status":null,"license":null,"views":0,"total_file_size_bytes":0,"version_count":0,"fair_f":null,"fair_a":null,"fair_i":null,"fair_r":null,"fair_zscore":null,"fair_rationale":null,"fair_model":null,"fair_agent_version":null,"fair_fulltext_source":null,"fair_has_llm":null,"fair_computed_at":null,"clinical_trials":[],"software_tools":[],"db_accessions":[],"linked_datasets":[],"topics":[]}